Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics and emerging therapies.

"Additionally, thyroid dysfunction and environmental ... Patients who are more likely to experience exacerbations based on ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

Myasthenia Gravis [MG] is characterized as an autoimmune ... first-generation anti-FcRn in the targeting of patients with Thyroid Eye Disease or TED. This leads to the next program I'm going ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

The myasthenia gravis trial linked low and high doses of ... next steps Immunovant has left the door open for batoclimab in thyroid eye disease. The biotech plans to make a final decision on ...

Wednesday, Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG ... 3 studies of batoclimab in thyroid eye disease are available.

Citing topline data, New York-based Immunovant (NASDAQ:IMVT) said its Phase 3 MG trial for the FcRn inhibitor met its primary endpoint in adults with myasthenia gravis. Meanwhile, initial data ...

I'm Dr. John Whyte, the Chief Medical Officer of WebMD. Today, I want to talk about a serious autoimmune condition called myasthenia gravis. It comes from the Latin and Greek which means grave ...